How Can The Laboratory Improve The Targeted Therapy Experience For Physicians? | Diaceutics

How Can The Laboratory Improve The Targeted Therapy Experience For Physicians?

October 5th, 2016

How Can The Laboratory Improve The Targeted Therapy Experience For Physicians?

It’s easy to forget or even be unaware that laboratories are a crucial cog in personalized medicine. Obviously they run the diagnostic tests that determine which treatment will suit a patient, and they may also develop these tests, but their influence becomes clear when we recognise that they also connect with physicians at the laboratory-physician interface (LPI).

The LPI is a primary and untapped channel of education, information and data flow. It is recognised as having the highest volume of medical transactions within the healthcare system today with thousands of daily transactions and hours of highly-trusted two-way communication between US therapy prescribers and testing labs. It has a disproportionate role in driving clinical decision-making and the potential to improve test adoption.

This is because when a test works and the result is easy to interpret then a doctor is more likely to reach for this test again over another test that may cause more difficulties. The net result from confidence around the testing and results process is increased test adoption. But surely if a test needs to be run the doctor will use it? Not always, and this is where the lab and its improving connections with physicians can really make an impact.

When pharma understands and values the laboratory as a key stakeholder it can actively support and develop its role. Specific LPI platforms (mechanisms, usually web-based) can support the test ordering and reporting process and provide physicians with information such as access to laboratory testing. They also have the potential to:

  • produce reports that are more actionable
  • educate physicians through the laboratory about best practice
  • capture important reporting information as efficiently as possible

Laboratories without dedicated platforms can still strengthen that link and trust with physicians with a simple approach to reporting. A graphical and numerical presentation of results is much easier to interpret and could incorporate current standard of care guidelines that enable physicians to give high quality care based on clear results. Physicians will stop using a test if they find the ordering or reporting process too complex, so it makes sense to address something that seems relatively basic.

But labs are coming into their own as physicians explore direct contact around results reporting and follow on treatment in a relationship that is becoming increasingly important. Leveraging this dynamic in combination with the specialist knowledge found in the labs and the LPI, could ensure faster adoption of the personalized medicine solution.

So when we contemplate the future of personalized medicine, laboratories should rank much higher up the list of important stakeholders and jump to mind much more quickly when we look for new opportunities.

Lab Blog Call to Action

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications